63 results about "D-tagatose" patented technology

A combination of one or more non-nutritive sweeteners, a sugar alcohol and D-tagatose are included in a reduced-calorie beverage or food product to achieve a taste substantially similar to that of a full-calorie beverage or food product. The combination is suitable for use in reduced-calorie frozen carbonated beverages. Preferably, the one or more non-nutritive sweeteners include one or more steviosides, a Stevia glycoside, a derivative of a Stevia glycoside, a glycoside of steviol, or a Lo Han Guo extract.

There is disclosed a method for disrupting biofilm and for inhibiting biofilm formation in an aqueous environment that comprises contacting said environment with an effective amount of D-tagatose.

Object: To provide a composition for preventing periodontal diseases (prophylactic agent of periodontal diseases), the composition having an excellent cariostatic property, being safe and stable for prolonged use and having less effects on flavor.Means for Resolution: A non-cariogenic material prepared by blending a rare sugar in the D form as selected from the group consisting of D-psicose, D-sorbose and D-tagatose, a rare sugar in the L form as selected from L-fructose, L-psicose and L-tagatose, or allitol as a rare sugar derivative, singly or in combination. A cariostatic agent comprising D-psicose, D-sorbose, D-tagatose, L-fructose, L-psicose and / or L-tagatose. A cariostatic agent in combination with catechins.

A reduced calorie frozen beverage comprising: (a) at least one non-nutritive sweetener, (b) erythritol, (c) D-tagatose, (d) maltodextrin, and (e) a nutritive sweetener.

A combination of a sugar alcohol and D-tagatose is used to produce naturally sweetened, diet beverages or food products. The sugar alcohol and D-tagatose can also be used in combination with one or more nutritive sweeteners to lower the calories of a full-calorie beverage or food product while preserving the taste.

Recombinant microorganisms are useful for producing xylitol by fermentation of arabinose. The recombinant microorganisms are produced by transformation of host microorganisms with heterologous polynucleotide sequences coding for each of L-xylulose reductase, D-tagatose 3-epimerase, and L-arabinose isomerase, which transformants express the heterologous polynucleotides at a sufficient functional level to be effective to produce xylitol from arabinose. Production of xylitol is effected by contacting these recombinant microorganisms with a substrate comprising arabinose under conditions effective to produce xylitol from arabinose.

A novel L-arabinose isomerase active enzyme and its corresponding gene, derived from a thermophilic source are provided. The enzyme is suitable for the production of D-tagatose, a useful low-calorie sweetener. The enzyme may be obtained from a Thermoanaerobacter species such as Thermoanaerobacter mathranii.

Screening for a glucokinase-activating substance among rare sugars and providing a composition for treating disordered conditions in association with glucokinase activity, the composition containing the glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm, the promoting agent containing D-psicose and / or D-tagatose as the active ingredient, or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and / or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions. The disordered conditions in association with glucokinase activity are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity. The composition is in a pharmaceutical form, and contains D-psicose and / or D-tagatose together with one or more pharmaceutically acceptable carriers.

The invention discloses a high temperature resistant L-arabinose isomerase which has an amino acid sequence shown in SEQ ID NO:2. The invention also discloses a gene sequence for encoding the high temperature resistant L-arabinose isomerase, a gene engineering bacterium and construction method thereof, an expression method for the L-arabinose isomerase, and application of the L-arabinose isomerase and the gene engineering bacterium in preparing D-tagatose. The reaction temperature of the high temperature resistant L-arabinose isomerase is 40 to 70 DEG C, and the reaction pH is 5.5 to 7.5. The recombinase shows good heat stability and pH tolerance; the added low-concentration Mn2+, Co2+ ions can greatly improve enzyme activity and heat stability; and the high temperature resistant L-arabinose isomerase has wide application prospect and economic significance for industrial production of the novel functional sweetener D-tagatose.

A hexuronate C4-epimerase with improved conversion activity and a method for producing D-tagatose using the hexuronate C4-epimerase. The hexuronate C4-epimerase includes an amino acid sequence set forth in SEQ ID NO: 1, in which serine (S) at position 125, serine (S) at position 185, valine (V) at position 267, serine (S) at position 268, threonine (T) at position 272, tryptophan (W) at position 306, arginine (R) at position 386 and tyrosine (Y) at position 403 from an N-terminal of hexunorate C4-epimerase are mutated.

A combination of a sugar alcohol and D-tagatose is used to produce naturally sweetened, diet beverages or food products. The sugar alcohol and D-tagatose can also be used in combination with one or more nutritive sweeteners to lower the calories of a full-calorie beverage or food product while preserving the taste.

The current disclosure provides a process for enzymatically converting a saccharide into tagatose. The invention also relates to a process for preparing tagatose where the process involves converting fructose 6-phosphate (F6P) to tagatose 6-phosphate (T6P), catalyzed by an epimerase, and converting the T6P to tagatose, catalyzed by a phosphatase.

Oral intake of D-tagatose in a prebiotic food induces production of butyrate and stimulates the growth of beneficial bacteria in the human colon. Therefore it is believed to be useful in food or the like as preventive drug against colon cancer.

The invention belongs to the biotechnology field, and relates particularly to genetically engineered bacteria by using recombinant DNA technology to construct high expressing L-arabinose isomerase, and a method for synthesizing tagatose by using the L-arabinose isomerase produced by genetically engineered bacteria. The genetically engineered bacteria can efficiently express the L-arabinose isomerase, the L-arabinose isomerase produced by the genetically engineered bacteria can be uses enzyme source to synthesize D-tagatose in the presence of the catalysis of D-galactose. The method has the advantages of simpleness, high efficiency, short period, etc, and the immobilized L- arabinose isomerase can be repeatedly used for more than ten times, thus being suitable for industrialized production.

The invention concerns identification of a gene encoding a novel L-arabinose isomerase of the Bacillus stearothernivphilus strain US 100 (L-AI US 100), a L-arabinose isomerase expressed from said gene, recombinant vectors harbouring said gene, microorganisms transformed with said vector, a protocol for preparing and purifying said recombinant protein, biochemical and kinetic characterization of said recombinant enzyme and a method for bioconversion of a D-galactose solution into a solution rich in D-tagatose using said polypeptide. This novel protein has original characteristics, in particular its independence from metal ions for its activity and its low need for such ions for its thermostability, as well as its potential for isomerizing D-galactose into D-tagatose with great efficacy of about 48% after 7 hours at 70° C.

A novel L-arabinose isomerase active enzyme and its corresponding gene, derived from a thermophilic source are provided. The enzyme is suitable for the production of D-tagatose, a useful low-calorie sweetener. The enzyme may be obtained from a Thermoanaerobacter species such as Thermoanaerobacter mathranii.

The invention discloses a recombinant L-arabinose isomerase (L-AI) as well as a gene and preparation method thereof and a method for preparing D-tagatose by utilizing the L-AI. Especially bacillus subtilis is used for expressing L-arabinose isomerase, the recombinant L-arabinose isomerase with biological activity is obtained, and the L-AI is more beneficial to industrial production of D-tagatose. The preparation method disclosed by the invention has the characteristic of simplicity, high efficiency and short cycle.

The invention provides an incretin-associated medicine capable of restraining secretion of GIP completely and promoting secretion of GLP-1 and highly safe. The medicine capable of promoting the secretion of GLP-1 (glucagon-like peptide-1) and restraining the secretion of the GIP (glucose-dependent insulinotropic peptide) comprises non-antagonistic inhibitor of clastic enzyme of cane sugar, such as L-gum sugar, D-wood sugar and D-tagatose, as an active ingredient.

The invention relates to a method for preparing D-tagatose and L-tagatose from dulcitol in the technical field of biology, which comprises the following steps: preparing a culture medium; inoculating acid-producing bacteria into the culture medium to prepare primary seed liquid and secondary seed liquid; culturing the second seed liquid to obtain a water solution containing the D-tagatose and the L-tagatose. The invention also relates to a preparation method adopting resting cell technology, which comprises the following steps: inoculating the acid-producing bacteria into the culture medium to be cultured; centrifugating the cultured bacteria after finishing the to form somatic cells, suspending the somatic cells by using the water solution containing the D-tagatose, and culturing the water solution to obtain the water solution containing the D-tagatose and the L-tagatose. The invention also relates to a preparation method adopting immobilized cell technology, which comprises the following steps: inoculating the acid-producing bacteria into the culture medium to be cultured; centrifugating the cultured bacteria after finishing the culture to obtain somatic cells; obtaining the water solution containing the D-tagatose and the L-tagatose by adopting the immobilized cell technology. The methods of the invention are green and safe, have high conversion efficiency, and can prepare the D-tagatose and the L-tagatose of pharmaceutical grade.

The invention discloses L-AI (L-arabinose isomerase). The L-AI is prepared through the step as follows: 279th phenylalanine of L-AI of Bacillus coagulans NL01 is mutated into isoleucine, and the L-AI is obtained, wherein the GenBank registration number of a nucleotide sequence of an L-AI gene araA is KX356659. The invention further discloses escherichia coli containing the L-AI as well as a construction method and an application of the escherichia coli. According to the constructed recombinant escherichia coli, F279I expressed by the escherichia coli has high catalytic efficiency on D-galactose. The optimal reaction temperature of a whole-cell catalysis reaction system is mild, a browning reaction can be avoided, and the L-AI better facilitates industrial production of D-tagatose when compared with wild type L-AI and other common L-AI from thermophilic bacteria and thermoacidophiles. Meanwhile, the whole-cell catalysis reaction system adopts simple components and has greater industrial production and application potential and economic value.

The invention discloses a method for preparing D-tagatose by an enzyme process. The method comprises the following steps: 1) separately establishing engineering bacteria containing galactitol dehydrogenase gene and engineering bacteria containing NADH oxidase gene or establishing coexpression engineering bacteria containing galactitol dehydrogenase gene and NADH oxidase gene; 2) fermenting the established engineering bacteria to obtain a whole cell containing galactitol dehydrogenase and NADH oxidase; and 3) with the whole cell containing galactitol dehydrogenase and NADH oxidase or the free enzyme of galactitol dehydrogenase and NADH oxidase as a catalyst, catalyzing the galactitol by taking NAD+ as a hydrogen acceptor in a weakly alkaline condition to obtain D-tagatose. Compared with traditional production method depending on L-arabinose isomerase, in the invention, the substrate conversion rate is high (>99.0%) and the product is easy to separate; and moreover, the co-product of a coenzyme circulation system adopted in the method is water which does not influence the separation and purification of the principal product.

The current disclosure provides a process for enzymatically converting a saccharide into tagatose. The invention also relates to a process for preparing tagatose where the process involves converting fructose 6-phosphate (F6P) to tagatose 6-phosphate (T6P), catalyzed by an epimerase, and converting the T6P to tagatose, catalyzed by a phosphatase.

The present invention relates to a low calorie coffee mix composition with a natural sweet taste prepared by using D-tagatose instead of sugar for a diet or a low calorie coffee mix.

The present invention is directed towards genetic modification of native gene encoding for D-tagatose 3-epimerase and rhamnose isomerase to substantially increase the expression level of these enzymes and use of said enzymes in a process to produce rare monosaccharides such as psicose and allose. Also disclosed in the present invention is expression constructs comprising the modified genes and a host cells to express the same.

Pharmaceutical compositions including D-tagatose along with a stilbene or stilbenoid component, or a salt or derivative thereof. Methods of prophylaxis and therapy by administering to a mammal a pharmaceutically effective amount of D-tagatose, optionally in combination with a stilbene or stilbenoid component, or a salt or derivative thereof to prevent or treat atherosclerosis, the metabolic syndrome, obesity, or diabetes.

The invention relates to an L-arabinose isomerase gene L-AI separated from Bacillus sp. SYBC hb4 and its cloning and expression method and use, and belongs to the field of bioengineering. The method comprises separating L-AI from Bacillus sp. SYBC hb4, constructing an expression vector pCold II-ai, and transferring the expression vector pCold II-ai into an escherichia coli expression strain BL21(DE3) so that high-efficiency expression is realized. The recombinase arabinose isomerase can utilize lactose produced by industrial production under the action of lactase to refine waste water and produce D-tagatose. The D-tagatose is a novel low-energy sweetener and can reduce obesity. The D-tagatose has effects of reducing blood sugar, is suitable for diabetic patients, can improve intestinal tract flora and can inhibit intestinal tract pathogenic bacteria. D-tagatose has a great application prospect in fields of medicines and industry.

The present invention relates to the development of an L-arabinose isomerase variant from Thermotoga neapolitana DSM 5068, which is a kind of thermophile, on the basis of protein molecular modeling. Moreover, the present invention relates to a method of producing D-tagatose from D-galactose by using the enzyme or a microorganism of the genus Corynebacterium expressing the enzyme.

A composition for treating disordered conditions in association with glucokinase activity contains a glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm contains D-psicose and / or D-tagatose as the active ingredient or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and / or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity.

The invention belongs to the field of biology and chemical industry, and particularly discloses a method for continuously producing D-tagatose by adopting D-galactose as a raw material on the basis of enzymatic isomerization reaction and a continuous chromatographic separation in-situ coupling technology. The method comprises the following steps of preparing a buffering solution; adequately dissolving the thermophilic L-arabinose isomerase in the water to obtain an enzyme solution; adequately dissolving D-galactose in the water to obtain a raw material solution; mixing and preheating the raw material solution, the buffering solution and the enzyme solution to obtain a feeding solution of a simulated moving bed reactor (SMBR); and placing the feeding solution into the SMBR to obtain a D-tagatose product solution through the in-situ reaction and separation. By determining the appropriate operating condition of the SMBR, the conversion rate of the D-galactose reaches more than 80 percent, the purity of the D-tagatose reaches more than 95 percent, and the yield is more than 80 percent. The method is low in cost, less in pollution and high in conversion rate; moreover, continuity in production can be realized, the consistency of the product quality can be guaranteed, and the commercialized application prospect is good.